|
Circulating BCAAs
|
GRS in classified mode
|
GRS in continuous mode
|
|---|
|
< 22 (n = 293)
|
22–24 (n = 279)
|
≥ 25 (n = 296)
|
Effect size
|
P for trend
|
Effect size
|
P value
|
|---|
|
Total BCAAs
|
139.5(26.8)
|
140.5(25.7)
|
146.3(31.5)b
|
3.6(1.1)
|
0.002
|
0.028(0.010)
|
0.003
|
|
Isoleucine
|
24.3(8.6)
|
23.5(8.76)
|
24.9 (8.8)
|
0.4 (0.4)
|
0.27
|
0.004(0.007)
|
0.59
|
|
Leucine
|
16.1(7.1)
|
15.6(8.32)
|
15.9(7.9)
|
0.09(0.3)
|
0.29
|
-0.001(0.007)
|
0.86
|
|
Valine
|
99.1(21.9)
|
101.4(20.5)
|
106.0(25.0)b
|
3.0(0.9)
|
0.001
|
0.031(0.009)
|
0.001
|
- The general linear model was used for estimation of mean (SD) for circulating BCAAs and linear regression model for β coefficient (SE)
- BCAAs branched-chain amino acids, GRS genetic risk score, T2D type 2 diabetes
- aResults were adjusted for age, sex, BMI, current drinkers, current smokers, exercise regularly, family history of diabetes, cardiovascular disease, red meat intake, and total energy intake.
- bComparing to the lowest GRS group, P < 0.05.
